{
    "Trade/Device Name(s)": [
        "Prosigna Breast Cancer Prognostic Gene Signature Assay"
    ],
    "Submitter Information": "NanoString Technologies, Inc.",
    "510(k) Number": "K130010",
    "Predicate Device Reference 510(k) Number(s)": [
        "K062694",
        "K081092"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NYI",
        "NSU"
    ],
    "Summary Letter Date": "September 6, 2013",
    "Summary Letter Received Date": "August 9, 2013",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.6040"
    ],
    "Regulation Name(s)": [
        "Gene expression profiling test system for breast cancer prognosis"
    ],
    "Analyte Class(es)": [
        "cancer molecular",
        "genetic molecular",
        "anatomic pathology"
    ],
    "Analyte(s)": [
        "50 classifier genes (PAM50)",
        "8 housekeeping genes"
    ],
    "Specimen Type(s)": [
        "Formalin-fixed, paraffin-embedded (FFPE) breast tumor tissue"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "NanoString nCounter Dx Analysis System",
        "Prep Station",
        "Digital Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Nucleic acid hybridization",
        "Digital gene expression profiling",
        "Multiplex gene expression measurement"
    ],
    "Methodologies": [
        "Gene expression profiling",
        "Molecular expression testing",
        "Multiplex hybridization"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "System",
        "Platform",
        "Software",
        "Cartridge",
        "Prep Plate"
    ],
    "Document Summary": "FDA 510(k) summary for NanoString Prosigna Breast Cancer Prognostic Gene Signature Assay for assessing risk of distant recurrence in postmenopausal women with HR+ breast cancer using gene expression profiling.",
    "Indications for Use Summary": "Qualitative assay for postmenopausal women with HR+ invasive breast carcinoma, performed on the NanoString nCounter Dx Analysis System using FFPE tissue, generating risk category and score for distant recurrence; indicated for both lymph node-negative Stage I/II and node-positive (1-3 nodes) Stage II patients to be treated with adjuvant endocrine therapy alone, in conjunction with other clinicopathological factors.",
    "fda_folder": "Immunology"
}